Product Description
Imipenem and cilastatin combination is used in the treatment of infections caused by bacteria. It works by killing bacteria or preventing their growth. This medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/imipenem-and-cilastatin-intravenous-route-intramuscular-route/description/drg-20062005)
Mechanisms of Action: DPEP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Urinary Tract Infections | Nephritis | Pyelonephritis | Endocarditis | Seizures | Endocarditis, Bacterial | Respiratory Tract Infections | Urinary Tract Infections
Known Adverse Events: Hypertension | Phlebitis | Headache | Diarrhea | Tachycardia | Hypotension | Seizures | Dizziness | Pain Unspecified | Erythema | Urticaria | Enteritis | Gastroenteritis | Pruritus | Candidiasis | Candidiasis, Oral | Anuria | Oliguria
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Israel, Spain, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Bronchitis|Communicable Diseases|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Pyelonephritis|Urinary Tract Infections
Phase 2: Acute Respiratory Distress Syndrome|Anal Cancer|Febrile Neutropenia
Phase 1: Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HRS-8427-302 | P3 |
Recruiting |
Communicable Diseases|Pyelonephritis|Urinary Tract Infections |
2025-11-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Pyelonephritis|Urinary Tract Infections |
2025-06-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Pyelonephritis|Urinary Tract Infections |
2025-06-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Pyelonephritis|Urinary Tract Infections |
2025-06-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2025-04-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2025-04-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2025-04-01 |
|
| HRS-8427-202 | P2 |
Not yet recruiting |
Communicable Diseases|Urinary Tract Infections|Pyelonephritis |
2024-06-01 |
24% |
| HRS-8427-202 | P2 |
Not yet recruiting |
Communicable Diseases|Urinary Tract Infections|Pyelonephritis |
2024-06-01 |
24% |
| HRS-8427-202 | P2 |
Not yet recruiting |
Communicable Diseases|Urinary Tract Infections|Pyelonephritis |
2024-06-01 |
24% |